Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 / 2 Study of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours

NCT05116891 is registered in ClinicalTrials.gov with Cantargia AB as lead sponsor.

NCT NCT05116891
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05116891 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 / 2 Study of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours
Lead sponsor
Cantargia AB
Phase
Phase 1/2
Overall status
Completed
Start date
September 22, 2021
Completion date
June 23, 2023
Enrollment
40 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, biliary tract cancer, colorectal cancer, non small cell lung cancer